Acute Myelogenous Leukemia (AML) is the most common acute leukemia in adults. Most patients are over 65 years of age and the incidence increases with advanced age. AML is characterized by the sludging of blasts in the microvasculature due to leukostasis (blast count > 100,000/mm³). Bone marrow biopsy will demonstrate > 20% blasts. Patients may experience fatigue (anemia), infection (neutropenia), bleeding (thrombocytopenia), CNS symptoms (somnolence, seizure, and stroke), and disseminated intravascular coagulation (DIC). The presence of Auer rods on microscopy is pathognomonic for AML. Management includes combination chemotherapy followed by postremission therapy.